Mga Batayang Estadistika
| LEI | 9845003BE146D3B75D32 |
| CIK | 1830487 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pharvaris N.V.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 12, 2025 |
Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements For the six months ended June 30, 2025 Contents Unaudited condensed consolidated statement of loss and other comprehensive (loss) /income 3 Unaudited condensed consolidated statement of financial position 4 Unaudited condensed consolidated statement of changes in equity 5 Unaudited condensed consolidated stat |
|
| August 12, 2025 |
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update • Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025 • Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026 • Startup activities |
|
| August 12, 2025 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive off |
|
| July 24, 2025 |
8,250,000 ordinary shares pre-funded warrants to purchase up to 500,000 ordinary shares Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-278650 PROSPECTUS SUPPLEMENT (to Prospectus dated April 12, 2024) 8,250,000 ordinary shares pre-funded warrants to purchase up to 500,000 ordinary shares We are offering 8,250,000 of our ordinary shares, par value €0.12 per ordinary share (“ordinary shares”) and, to one investor, pre-funded warrants to purchase up to 500,000 ordinary |
|
| July 24, 2025 |
EX-1.1 Exhibit 1.1 8,250,000 Ordinary Shares (Nominal Value €0.12 Per Ordinary Share) Pre-Funded Warrants to Purchase 500,000 Ordinary Shares (Nominal Value €0.12 Per Ordinary Share) PHARVARIS N.V. UNDERWRITING AGREEMENT July 22, 2025 July 22, 2025 Morgan Stanley & Co. LLC Leerink Partners LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Morgan Stanley & Co. LLC |
|
| July 24, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July, 2025 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive off |
|
| July 24, 2025 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables F-3 Pharvaris N.V. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filin |
|
| July 24, 2025 |
FORM OF PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT PHARVARIS N.V. EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT PHARVARIS N.V. Warrant Shares: [ ] Date of Issuance: [ ] (such date, the “Issue Date”) Warrant No.: [ ] THIS PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitati |
|
| July 23, 2025 |
$175,000,000 ordinary shares pre-funded warrants to purchase up to ordinary shares FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated July 22, 2025 Relating to Preliminary Prospectus Supplement Dated July 22, 2025 Registration Statement No. |
|
| July 22, 2025 |
SUBJECT TO COMPLETION DATED JULY 22, 2025 424B5 Table of Contents The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| July 10, 2025 |
EX-99.1 Exhibit 99.1 Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 • Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026 ZUG, Switzerland, July 10, 2025 – Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B |
|
| July 10, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive o |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offic |
|
| June 10, 2025 |
Exhibit 99.2 CONVENING NOTICE This is the convening notice for the Annual General Meeting of shareholders of Pharvaris N.V. (the "Company") to be held on June 27, 2025 at 4:00 p.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch statutory board report for the fiscal |
|
| June 10, 2025 |
Pharvaris Announces Annual Meeting of Shareholders Exhibit 99.1 Pharvaris Announces Annual Meeting of Shareholders Zug, Switzerland, June 10, 2025 – Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offic |
|
| June 10, 2025 |
1Table of Contents Exhibit 99.4 Pharvaris N.V. Annual Report for the fiscal year ended December 31, 2024 1Table of Contents Exhibit 99.4 Pharvaris N.V. TABLE OF CONTENTS Page Report of Board of Directors 1 Introduction 2 1.1 Preparation 2 1.2 Forward-looking statements 2 2 Business 4 2.1 History and development of the company 4 2.2 Overview 4 2.3 Organizational structure 44 2.4 Property, plants an |
|
| June 10, 2025 |
Exhibit 99.3 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the "Principal"). DECLARES AS FOLLOWS 1. The Principal hereby registers for the annual general meeting of shareholders of Pharvaris N.V. (the "Company") to be held on June 27, 2025 at 4:00 p.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amst |
|
| May 13, 2025 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive office |
|
| May 13, 2025 |
Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements For the three months ended March 31, 2025 Contents Unaudited condensed consolidated statement of loss and other comprehensive income 3 Unaudited condensed consolidated statement of financial position 4 Unaudited condensed consolidated statement of changes in equity 5 Unaudited condensed consolidated statement |
|
| May 13, 2025 |
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update • Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026 • Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidenc |
|
| April 7, 2025 |
Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David Nassif, certify that: 1. I have reviewed this annual report on Form 20-F of Pharvaris N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a m |
|
| April 7, 2025 |
Exhibit 2.1 Description of Ordinary Shares of the Registrant As of the date of the Annual Report on Form 20-F of which this Exhibit 2.1 is a part, Pharvaris N.V. (the “Company”, “we”, “us” or “our”) has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended; our registered ordinary shares. We are registered with the Trade Register of the Chamber |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 acc FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) |
|
| April 7, 2025 |
Exhibit 11.1 INSIDER TRADING POLICY PHARVARIS N.V. ARTICLE 1 INTRODUCTION This document sets out the Company’s insider trading policy. ARTICLE 2 DEFINITIONS AND INTERPRETATION 2.1 In this policy the following definitions shall apply: Article An article of this policy. Board The Company’s board of directors. CEO The Company’s chief executive officer. Chairman The chairman of the Board. Company Phar |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offi |
|
| April 7, 2025 |
I, Berndt Modig, certify that: Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Berndt Modig, certify that: 1. I have reviewed this annual report on Form 20-F of Pharvaris N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a m |
|
| April 7, 2025 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Pharvaris N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Nassif, Chief Financial Officer of the Company, certify |
|
| April 7, 2025 |
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Exhibit 99.1 Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update • Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelines • Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topli |
|
| April 7, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Pharvaris N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Berndt Modig, Chief Executive Officer of the Company, certify |
|
| April 7, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-252897) and Form F-3 (Nos 333-273757 and 333-277705 and 333-278650) of Pharvaris N.V. of our report dated April 7, 2025 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers Accounta |
|
| April 7, 2025 |
Exhibit 97.1 PURPOSE CLAWBACK POLICY PHARVARIS N.V. Pharvaris N.V. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Company’s Board of Directors (the “Board”) has therefore adopted this policy w |
|
| January 13, 2025 |
Pharvaris Outlines 2025 Strategic Priorities Exhibit 99.1 Pharvaris Outlines 2025 Strategic Priorities • Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026 • Enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026 • |
|
| January 13, 2025 |
Pioneering science for patient choice Corporate Presentation January 2025 Exhibit 99. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive of |
|
| November 13, 2024 |
Three months ended September 30, Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2024 Contents Unaudited condensed consolidated statement of Loss and Other Comprehensive Income 3 Unaudited condensed consolidated statement of financial position 4 Unaudited condensed consolidated statement of changes in equity 5 Unaudited condensed consolidated statem |
|
| November 13, 2024 |
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates Exhibit 99.1 Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates • Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congresses • Intend to engage in clinical development of deucrictibant for the treatment of acquired angioedema due to C1-IN |
|
| November 13, 2024 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive o |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive |
|
| September 23, 2024 |
Execution Version Exhibit 99.1 Amendment 2 to the License Agreement entered into by AnalytiCon Discovery GmbH and Pharvaris NV on 31st March 2016, This Amendment 2 is made between Pharvaris Netherlands BV Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands “Pharvaris” and BRAIN Biotech AG Darmstädter Str. 34 - 36, 64673 Darmstadt, Germany “BRAIN Biotech” BRAIN Biotech and Pharvaris in the following |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive |
|
| September 5, 2024 |
Pharvaris Presents Data at the Bradykinin Symposium 2024 EX-99.1 2 phvs-ex991.htm EX-99.1 Exhibit 99.1 Pharvaris Presents Data at the Bradykinin Symposium 2024 ZUG, Switzerland, September 5, 2024 - Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced a summary of data being presented at the ongoing 7th Bradykini |
|
| September 5, 2024 |
Exhibit 99.2 Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 • Extension data confirm the observed safety and tolerability profile from Phase 2 studies and further support the potential for deucrictibant to become a preferred therapy for the management of HAE • Long-term prophylaxis extension data o |
|
| September 5, 2024 |
6-K 1 6-kprseptember5.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (A |
|
| September 5, 2024 |
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant Exhibit 99.3 Pharvaris Provides Business Update and Expands Development Program for Deucrictibant • CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024 • Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real- |
|
| September 5, 2024 |
Pioneering science for patient choice Corporate Presentation September 2024 Exhibit 99. |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive off |
|
| August 14, 2024 |
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update • Alignment with regulatory agencies following End-of-Phase 2 meetings for the prophylactic development of deucrictibant; global startup activities of CHAPTER-3, pivotal Phase 3 study of deucrictibant for the prevention of hereditary angioedema (HAE) attacks, underway • Enrollment of RAPIDe-3, a globa |
|
| August 14, 2024 |
Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements For the six months ended June 30, 2024 Contents Unaudited condensed consolidated statement of Loss and Other Comprehensive Income 3 Unaudited condensed consolidated statement of financial position 4 Unaudited condensed consolidated statement of changes in equity 5 Unaudited condensed consolidated statement of |
|
| August 14, 2024 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offic |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offic |
|
| June 11, 2024 |
Exhibit 99.3 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the "Principal"). DECLARES AS FOLLOWS 1. The Principal hereby registers for the annual general meeting of shareholders of Pharvaris N.V. (the "Company") to be held on June 28, 2024 at 3:00 p.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amst |
|
| June 11, 2024 |
Exhibit 99.4 Pharvaris N.V. Annual Report for the fiscal year ended December 31, 2023 Pharvaris N.V. TABLE OF CONTENTS Page Report of Board of Directors 1 Introduction 2 1.1 Preparation 2 1.2 Forward-looking statements 2 2 Business 4 2.1 History and development of the company 4 2.2 Overview 4 2.3 Organizational structure 36 2.4 Property, plants and equipment 36 2.5 Operating results 36 2.6 Materia |
|
| June 11, 2024 |
Pharvaris Announces Annual Meeting of Shareholders Exhibit 99.1 Pharvaris Announces Annual Meeting of Shareholders Zug, Switzerland, June 11, 2024 – Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the annual general meeting of shareholders will take place on Friday, June 28, 2024, at 15:00 CEST (9:00 |
|
| June 11, 2024 |
Exhibit 99.2 CONVENING NOTICE This is the convening notice for the Annual General Meeting of shareholders of Pharvaris N.V. (the "Company") to be held on June 28, 2024 at 3:00 p.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch statutory board report for the fiscal |
|
| June 4, 2024 |
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses Exhibit 99.1 Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses • Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hours • High treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score compared to placebo Zug, Switzerland, June 4, 2024 – Pharvaris (Nasdaq: PHVS), a late-stage bio |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offic |
|
| May 8, 2024 |
Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements For the three months ended March 31, 2024 Contents Unaudited condensed consolidated statement of Loss and Other Comprehensive Income 3 Unaudited condensed consolidated statement of financial position 4 Unaudited condensed consolidated statement of changes in equity 5 Unaudited condensed consolidated statement |
|
| May 8, 2024 |
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update • RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrolling • End-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacks • Executing from a strong financial position with cash and cash |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive office |
|
| May 8, 2024 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| April 12, 2024 |
PHARVARIS N.V. Ordinary Shares (nominal value of €0.12 per share) SALES AGREEMENT Exhibit 1.2 PHARVARIS N.V. Ordinary Shares (nominal value of €0.12 per share) SALES AGREEMENT April 12, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Pharvaris N.V., a public limited liability company (naamloze vennootschap) (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follo |
|
| April 12, 2024 |
As filed with the Securities and Exchange Commission on April 12, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 12, 2024 Registration No. |
|
| April 12, 2024 |
Pharvaris N.V. as the Company as Trustee Senior Indenture Dated as of [•], [•] Exhibit 4.2 Pharvaris N.V. as the Company and [•] as Trustee Senior Indenture Dated as of [•], [•] TABLE OF CONTENTS TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 5 ARTICLE 2 THE SECURITIES Section 2.01. Fo |
|
| April 12, 2024 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables FORM F-3 (Form Type) Pharvaris N. |
|
| April 12, 2024 |
Pharvaris N.V. as the Company as Trustee Subordinated Indenture Dated as of [•], [•] Exhibit 4.3 Pharvaris N.V. as the Company and [•] as Trustee Subordinated Indenture Dated as of [•], [•] TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions 1 Section 1.02. Other Definitions 5 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 6 ARTICLE 2 THE SECURITIES Section 2.01. Form and Datin |
|
| April 10, 2024 |
CLAWBACK POLICY PHARVARIS N.V. Exhibit 97.1 PURPOSE CLAWBACK POLICY PHARVARIS N.V. Pharvaris N.V. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Company’s Board of Directors (the “Board”) has therefore adopted this policy |
|
| April 10, 2024 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Pharvaris N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Berndt Modig, Chief Executive Officer of the Company, certify |
|
| April 10, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-252897) and Form F-3 (Nos 333-263198, 333-273757 and 333-277705) of Pharvaris N.V. of our report dated April 10, 2024 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers Accountant |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offi |
|
| April 10, 2024 |
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer Exhibit 99.2 Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer Zug, Switzerland, April 10, 2024 – Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of David Nassif, J.D., as Chief Financial Officer, effective April 15, 20 |
|
| April 10, 2024 |
I, Berndt Modig, certify that: Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Berndt Modig, certify that: 1. I have reviewed this annual report on Form 20-F of Pharvaris N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a m |
|
| April 10, 2024 |
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Exhibit 99.1 Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrolling • End-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacks • Strengthened executive committee with hiring |
|
| April 10, 2024 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Pharvaris N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anna Nijdam, Head of Strategic Finance and Principal Accounti |
|
| April 10, 2024 |
Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Anna Nijdam, certify that: 1. I have reviewed this annual report on Form 20-F of Pharvaris N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a ma |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 10, 2024 |
Exhibit 2.1 Description of Ordinary Shares of the Registrant As of the date of the Annual Report on Form 20-F of which this Exhibit 2.1 is a part, Pharvaris N.V. (the “Company”, “we”, “us” or “our”) has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended; our registered ordinary shares. We are registered with the Trade Register of the Chamber |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offi |
|
| March 6, 2024 |
As filed with the Securities and Exchange Commission on March 6, 2024 As filed with the Securities and Exchange Commission on March 6, 2024 Registration No. |
|
| March 6, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form F-3 (Form Type) Pharvaris N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Ca |
|
| March 6, 2024 |
1 Exhibit 3.1 This is a translation into English of the official Dutch version of a deed of amendment to the articles of association of a public limited liability company under Dutch law. In the event of a conflict between the English and Dutch texts, the Dutch text shall prevail. DEED OF AMENDMENT TO THE ARTICLES OF ASSOCIATION OF PHARVARIS N.V. On this day, the sixth day of March two thousand an |
|
| February 16, 2024 |
PROPOSED ARTICLES OF ASSOCIATION Exhibit 99.4 1 Note: this is a translation into English of the official Dutch version of a deed of amendment to the articles of association of a private limited liability company under Dutch law. Definitions included in article 1 below appear in the English alphabetical order, but will appear in the Dutch alphabetical order in the official Dutch version. In the event of a conflict between the Engl |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive o |
|
| February 16, 2024 |
Exhibit 99.3 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the "Principal"). DECLARES AS FOLLOWS 1. The Principal hereby registers for the extraordinary general meeting of shareholders of Pharvaris N.V. (the "Company") to be held on March 6, 2024 at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the |
|
| February 16, 2024 |
Exhibit 99.2 CONVENING NOTICE This is the convening notice for the extraordinary general meeting of shareholders of Pharvaris N.V. (the "Company") to be held on March 6, 2024 at 12:00 p.m. CET at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "EGM"). The agenda for the EGM is as follows: 1. Opening 2. Amendment to the Company's articles of association |
|
| February 16, 2024 |
Exhibit 99.5 1 VOORGESTELDE STATUTEN STATUTEN DEFINITIES EN INTERPRETATIE Artikel 1 1.1 In deze statuten gelden de volgende definities: Algemene Vergadering De algemene vergadering van de Vennootschap. Artikel Een artikel van deze statuten. Bestuur Het bestuur van de Vennootschap. Bestuurder Een lid van het Bestuur. Bestuursreglement Het reglement van het Bestuur, zoals vastgesteld door het Bestuu |
|
| February 16, 2024 |
Pharvaris Announces Extraordinary Meeting of Shareholders Exhibit 99.1 Pharvaris Announces Extraordinary Meeting of Shareholders Zug, Switzerland, February 16, 2024 – Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the extraordinary general meeting of shareholders will take place on Wednesday, March 6, 2024, at 12:00 CST |
|
| February 14, 2024 |
PHVS / Pharvaris N.V. / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246235d16sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pharvaris N.V. (Name of Issuer) Ordinary shares, par value €0.12 per share (Title of Class of Securities) N69605108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 14, 2024 |
PHVS / Pharvaris N.V. / VIKING GLOBAL INVESTORS LP Passive Investment SC 13G/A 1 sayw2402141613ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 3) Pharvaris N.V. (Name of Issuer) Ordinary shares, par value €0.12 par value per share (Title of |
|
| February 13, 2024 |
PHVS / Pharvaris N.V. / Foresite Capital Fund IV, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm245717d1sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3)* Pharvaris N.V. (Name of Issuer) Ordinary Shares, par value €0.12 (Title of Class of Securities) N69605108 (CUSIP Nu |
|
| February 13, 2024 |
PHVS / Pharvaris N.V. / GENERAL ATLANTIC LLC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 eh24044746413ga2-pharvaris.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Pharvaris N.V. (Name of Issuer) Ordinary shares, par value €0.01 per share (Title of Class of Securities) N69605108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this St |
|
| February 8, 2024 |
PHVS / Pharvaris N.V. / LSP V Cooperatieve U.A. - SC 13G/A Passive Investment SC 13G/A 1 d582194dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Pharvaris, N.V. (Name of Issuer) Ordinary Shares (Title of Class of Securi |
|
| February 7, 2024 |
PHARVARIS N.V. REGISTRATION RIGHTS AGREEMENT Exhibit 99.1 Execution Version PHARVARIS N.V. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of February 5, 2024 between Pharvaris N.V., a public company with limited liability (naamloze vennootschap) incorporated and existing under the laws of the Netherlands (the “Company”) and General Atlantic PH B.V. (the “Investor”). Except as otherwise specifie |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive o |
|
| January 25, 2024 |
PHVS / Pharvaris N.V. / venBio Global Strategic Fund III, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Pharvaris N.V. (Name of Issuer) Ordinary shares, par value €0.12 per share (Title of Class of Securities) N69605108 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Address and Telephone Num |
|
| January 25, 2024 |
EX-99.5 2 ef20019681ex99-5.htm EXHIBIT 99.5 Exhibit 99.5 SCHEDULE OF TRANSACTIONS The following table sets forth all transactions with respect to the Common Shares effected during the past sixty days prior to the filing of this Amendment No. 3 by any Reporting Person. All of these transactions were effected in the open market through a broker. Name Date of Transaction Transaction Amount of Securit |
|
| January 22, 2024 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.A 2 d737649dex99a.htm EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments th |
|
| January 22, 2024 |
Exhibit 99.1 Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks Zug, Switzerland, January 22, 2024 – Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the U.S. Food and Drug Administration (FDA) has lif |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive of |
|
| January 22, 2024 |
Corporate Presentation January 2024 Pioneering science for patient choice Exhibit 99. |
|
| January 22, 2024 |
PHVS / Pharvaris N.V. / Bain Capital Life Sciences Fund, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| January 8, 2024 |
Corporate Presentation January 2024 Pioneering science for patient choice Exhibit 99. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive of |
|
| January 8, 2024 |
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities • RAPIDe-3, a global Phase 3 clinical study of deucrictibant for the on-demand treatment of HAE, to initiate within 1H24 • Results of nonclinical rodent toxicology study submitted to the FDA • Jochen Knolle, Ph. |
|
| December 8, 2023 |
Exhibit 1.1 11,125,000 Shares Pre-Funded Warrants to Purchase 1,375,000 Shares PHARVARIS N.V. ORDINARY SHARES (NOMINAL VALUE €0.12 PER SHARE) UNDERWRITING AGREEMENT December 6, 2023 1 December 6, 2023 Morgan Stanley & Co. LLC Leerink Partners LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 1 |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive o |
|
| December 8, 2023 |
FORM OF PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT PHARVARIS N.V. Exhibit 4.1 FORM OF PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT PHARVARIS N.V. Warrant Shares: [ ] Date of Issuance: [ ] (such date, the “Issue Date”) Warrant No.: [ ] THIS PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on |
|
| December 7, 2023 |
11,125,000 ordinary shares pre-funded warrants to purchase up to 1,375,000 ordinary shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263198 PROSPECTUS SUPPLEMENT (to Prospectus dated March 10, 2022) 11,125,000 ordinary shares pre-funded warrants to purchase up to 1,375,000 ordinary shares We are offering 11,125,000 of our ordinary shares, par value €0.12 per share (“ordinary shares”) and, to one investor, pre-funded warrants to purchase up to 1,37 |
|
| December 6, 2023 |
Corporate Presentation December 2023 Pioneering science for patient choice Exhibit 99. |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive o |
|
| December 6, 2023 |
December 6, 2023 CHAPTER-1 Phase 2 Top-line Data Exhibit 99.2 Disclaimer This presentation includes data for an investigational product not yet approved by regulatory authorities. This Presentation contains certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do no |
|
| December 6, 2023 |
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated December 6, 2023 Relating to Prospectus Dated March 10, 2022 Registration Statement No. |
|
| December 6, 2023 |
Exhibit 99.4 ENFORCEABILITY OF JUDGMENTS We are organized and existing under the laws of the Netherlands. As such, under Dutch private international law, the rights and obligations of our shareholders vis-à-vis the company originating from Dutch corporate law and our Articles of Association, as well as the civil liability of our officers (functionarissen) (including our directors and executive off |
|
| December 6, 2023 |
Exhibit 99.3 Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks • Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo • 92.3% reduction in occurrence of moderate and severe attacks • 92.6% fewer attacks treated |
|
| November 30, 2023 |
PHVS / Pharvaris NV / Venrock Healthcare Capital Partners III, L.P. - SC 13G Passive Investment SC 13G 1 tm2331803d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Pharvaris N.V. (Name of Issuer) Ordinary shares, par value €0.12 per share (Title of Class of Securities) N69605108 (CUSIP Number) November 20, 2023 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| November 2, 2023 |
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update • Top-line data from Phase 2 CHAPTER-1 prophylactic study anticipated by YE2023 • Participated in an End-of-Phase 2 meeting with the FDA; initiation of global Phase 3 clinical study (RAPIDe-3) anticipated within 1H2024 • Cash and cash equivalents of €158 million as of September 30, 2023 Zug, Switzerlan |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive o |
|
| November 2, 2023 |
Three months ended September 30, Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements As of and for the three and nine months ended September 30, 2023 Contents Unaudited condensed consolidated statements of Loss and Other Comprehensive Loss 3 Unaudited condensed consolidated statements of financial position 4 Unaudited condensed consolidated statements of changes in equity 5 Unaudited condense |
|
| November 2, 2023 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| August 24, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-273757 PROSPECTUS Pharvaris N.V. (incorporated in the Netherlands) 6,951,340 Ordinary Shares Offered by Selling Securityholders This prospectus relates to the resale from time to time in one or more offerings by the selling stockholders identified herein or their permitted transferees (each, a “selling securityholder” and collectively, the “sel |
|
| August 15, 2023 |
Pharvaris N.V. Emmy Noetherweg 2 2333 BK Leiden The Netherlands August 15, 2023 Pharvaris N.V. Emmy Noetherweg 2 2333 BK Leiden The Netherlands August 15, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Pharvaris N.V. Registration Statement on Form F-3 Filing Date August 7, 2023 File No. 333-273757 REQUEST FOR ACCELERATION OF EFFECTIVENESS Pursuant to Rule 461 under the Securities Act of 1933, as |
|
| August 7, 2023 |
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update • Enrollment completed in Phase 2 CHAPTER-1 prophylactic study; top-line data anticipated by YE2023 • Clinical hold lifted on deucrictibant for the on-demand treatment of HAE; initiation of global Phase 3 clinical study (RAPIDe-3) anticipated by YE2023 • Completed $70 million private placement; cash a |
|
| August 7, 2023 |
As filed with the Securities and Exchange Commission on August 7, 2023 As filed with the Securities and Exchange Commission on August 7, 2023 Registration No. |
|
| August 7, 2023 |
Exhibit 99.4 RISK FACTORS The following risk factors should be read in conjunction with, and amend and supplement, those included in the Annual Report on Form 20-F filed by Pharvaris N.V. (“we”, “our”, “us” or the “Company”) on April 5, 2023 (the “Form 20-F or the “Annual Report”). Investing in the Company’s ordinary shares involves a high degree of risk. You should carefully consider the risks de |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive off |
|
| August 7, 2023 |
Exhibit Filing Fees Exhibit 107 CALCULATION OF FILING FEE TABLE Form F-3 (Form Type) Pharvaris N. |
|
| August 7, 2023 |
Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements As of and for the three and six months ended June 30, 2023 Contents Unaudited condensed consolidated statements of Loss and Comprehensive Loss 3 Unaudited condensed consolidated statements of financial position 4 Unaudited condensed consolidated statements of changes in equity 5 Unaudited condensed consolidat |
|
| August 7, 2023 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offic |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offic |
|
| June 27, 2023 |
MATERIAL UNITED STATES FEDERAL INCOME TAX AND DUTCH TAX CONSIDERATIONS Exhibit 99.1 MATERIAL UNITED STATES FEDERAL INCOME TAX AND DUTCH TAX CONSIDERATIONS The information presented under the caption “—Material U.S. Federal Income Tax Considerations to U.S. Holders” below is a discussion of material U.S. federal income tax consequences to a U.S. Holder (as defined below) of owning and disposing of our ordinary shares. The information presented under the caption “—Mate |
|
| June 26, 2023 |
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE Exhibit 99.1 Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE Zug, Switzerland, June 26, 2023 – Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical h |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offic |
|
| June 23, 2023 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completen |
|
| June 23, 2023 |
PHVS / Pharvaris NV / GENERAL ATLANTIC LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pharvaris N.V. (Name of Issuer) Ordinary shares, par value €0.01 per share (Title of Class of Securities) N69605108 (CUSIP Number) June 21, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offic |
|
| June 23, 2023 |
PHVS / Pharvaris NV / Bain Capital Life Sciences Fund, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| June 21, 2023 |
PHVS / Pharvaris NV / venBio Global Strategic Fund III, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Pharvaris N.V. (Name of Issuer) Ordinary shares, par value €0.12 per share (Title of Class of Securities) N69605108 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Address and Telephone Num |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offic |
|
| June 20, 2023 |
Exhibit 99.1 SUBSCRIPTION AGREEMENT Pharvaris N.V. Emmy Noetherweg 2 2333 BK Leiden The Netherlands Ladies and Gentlemen: Pharvaris N.V., a public company with limited liability (naamloze vennootschap), having its official seat in Leiden, the Netherlands, and registered with the trade register of the Dutch Chamber of Commerce under number 64239411 (the “Company”) desires to issue to the undersigne |
|
| June 20, 2023 |
Pharvaris Announces $70 Million Private Placement Financing Exhibit 99.2 Pharvaris Announces $70 Million Private Placement Financing ZUG, Switzerland, June 20, 2023 - Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that it has entered into |
|
| June 1, 2023 |
Exhibit 99.2 CONVENING NOTICE This is the convening notice for the annual general meeting of shareholders of Pharvaris N.V. (the "Company") to be held on June 23, 2023 at 3:00 p.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch statutory board report for the fiscal |
|
| June 1, 2023 |
Pharvaris Announces Annual Meeting of Shareholders Exhibit 99.1 Pharvaris Announces Annual Meeting of Shareholders Zug, Switzerland, June 1, 2023 – Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the annual general meeting of shareholders will take place on Friday, June 23, 2023, at 15:00 CEST (9:00 a.m. EDT). All |
|
| June 1, 2023 |
Pharvaris N.V. Annual Report for the fiscal year ended December 31, 2022 Table of Contents Exhibit 99.4 Pharvaris N.V. Annual Report for the fiscal year ended December 31, 2022 Table of Contents Pharvaris N.V. TABLE OF CONTENTS Page Report of Board of Directors 1 Introduction 3 1.1 Preparation 3 1.2 Forward-looking statements 3 2 Business 4 2.1 History and development of the company 4 2.2 Overview 5 2.3 Organizational structure 35 2.4 Property, plants and equipment 36 |
|
| June 1, 2023 |
Exhibit 99.3 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the "Principal"). DECLARES AS FOLLOWS 1. The Principal hereby registers for the annual general meeting of shareholders of Pharvaris N.V. (the "Company") to be held on June 23, 2023 at 3:00 p.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amst |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offic |
|
| May 8, 2023 |
Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements At March 31, 2023 Contents Unaudited condensed consolidated statements of Loss and Comprehensive Loss 3 Unaudited condensed consolidated statements of financial position 4 Unaudited condensed consolidated statements of changes in equity 5 Unaudited condensed consolidated statements of cash flows 6 Notes to th |
|
| May 8, 2023 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive office |
|
| May 8, 2023 |
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update • Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 (immediate-release deucrictibant capsules) for the prophylactic treatment of HAE, anticipated by YE2023 • Executing from a strong financial position with cash and cash equivalents of €135 million as of March 31, 2023 Zug, Switz |
|
| April 5, 2023 |
Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002. EXHIBIT 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Anna Nijdam, certify that: 1. I have reviewed this annual report on Form 20-F of Pharvaris N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a ma |
|
| April 5, 2023 |
Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002. EXHIBIT 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Berndt Modig, certify that: 1. I have reviewed this annual report on Form 20-F of Pharvaris N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a m |
|
| April 5, 2023 |
EXHIBIT 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Pharvaris N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anna Nijdam, Head of Finance and Principal Accounting Officer |
|
| April 5, 2023 |
Description of Ordinary Shares of the Registrant Exhibit 2.1 Description of Ordinary Shares of the Registrant As of the date of the Annual Report on Form 20-F of which this Exhibit 2.1 is a part, Pharvaris N.V. (the “Company”, “we”, “us” or “our”) has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended; our registered ordinary shares. We are registered with the Trade Register of the Chamber |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offi |
|
| April 5, 2023 |
Consent of PricewaterhouseCoopers Accountants N.V. Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-252897) and Form F-3 (No. 333-263198) of Pharvaris N.V. of our report dated April 5, 2023 relating to the financial statements, which appears in this Form 20-F. /s/ W. Voorthuijsen RA PricewaterhouseCoopers Accountants N.V. Am |
|
| April 5, 2023 |
EXHIBIT 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Pharvaris N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Berndt Modig, Chief Executive Officer of the Company, certify |
|
| April 5, 2023 |
Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Exhibit 99.1 Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update • Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 for the prophylactic treatment of HAE, anticipated in 2H2023 • 26-week non-clinical toxicology study intended to address the clinical holds in the U.S. initiated; submission of study results anticipated by YE2023 |
|
| March 10, 2023 |
6-K 1 svb.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of princi |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offi |
|
| March 8, 2023 |
Pioneering science for patient choice March 2023 Exhibit 99.1 Disclaimer This Presentation may contain certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do not relate to matters of historical fact should be considered forward-looking statements including, withou |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive o |
|
| February 14, 2023 |
Pioneering science for patient choice February 2023 Exhibit 99.1 Disclaimer This Presentation may contain certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do not relate to matters of historical fact should be considered forward-looking statements including, wit |
|
| February 14, 2023 |
PHVS / Pharvaris N.V. / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment SC 13G/A 1 brhc10047895sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 2) Pharvaris N.V. (Name of Issuer) Ordinary shares, par value €0.12 par value per shar |
|
| February 13, 2023 |
PHVS / Pharvaris N.V. / Foresite Capital Fund IV, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236260d1sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* Pharvaris N.V. (Name of Issuer) Ordinary Shares, par value €0.01 (Title of Class of Securities) N69605108 (CUSIP Nu |
|
| January 9, 2023 |
Pioneering science for patient choice January 2023 Exhibit 99.2 Disclaimer This Presentation may contain certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do not relate to matters of historical fact should be considered forward-looking statements including, with |
|
| January 9, 2023 |
Pharvaris Provides Regulatory, Clinical, and Corporate Updates EX-99.1 2 phvs-ex9916.htm EX-99.1 Exhibit 99.1 Pharvaris Provides Regulatory, Clinical, and Corporate Updates ZUG, Switzerland, January 9, 2023 – Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today provided business updates and company highlights. Business Updates and Company Hi |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive offi |
|
| December 8, 2022 |
Exhibit 99.1 Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks • Primary endpoint met, substantially reducing HAE attack symptoms • All secondary endpoints met • PHVS416 was well tolerated at all dose levels • Pharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, December 8, 2022 – Pharvaris (Nasdaq: P |
|
| December 8, 2022 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.3 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| December 8, 2022 |
RAPIDe-1 Phase 2 Top-line Data December 8, 2022 RAPIDe-1 Phase 2 Top-line Data December 8, 2022 Disclaimer This Presentation may contain certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive off |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive off |
|
| December 8, 2022 |
Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update Exhibit 99.2 Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update • Announced positive top-line data for RAPIDe-1, a global Phase 2 study of PHVS416 for the on-demand treatment of HAE attacks • Participated in a Type A meeting with the FDA regarding the previously announced holds on the clinical studies of PHA121 in the U.S. • Top-line data from CHAPTER-1, a global p |
|
| December 8, 2022 |
Three months ended September 30, Exhibit 99.4 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements As of and for the three and nine months ended September 30, 2022 Contents Page Unaudited condensed consolidated statements of profit or loss and other comprehensive income or loss 2 Unaudited condensed consolidated statements of financial position 3 Unaudited condensed consolidated statements of changes in eq |
|
| November 1, 2022 |
Pioneering science for patient choice November 2022 EX-99.1 Pioneering science for patient choice November 2022 EX-99.1 Disclaimer This Presentation may contain certain ?forward?looking statements? within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do not relate to matters of historical fact should be considered forward-looking statements including, without |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive off |
|
| September 26, 2022 |
Exhibit 99.3 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated: September 26, 2022 VENBIO |
|
| September 26, 2022 |
PHVS / Pharvaris N.V. / venBio Global Strategic Fund III, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pharvaris N.V. (Name of Issuer) Ordinary shares, par value €0.12 per share (Title of Class of Securities) N69605108** (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Address and Telephone N |
|
| September 12, 2022 |
Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update ? Formal letters received from FDA relating to the previously announced hold on clinical studies of PHA121 in the U.S. ? Top-line data anticipated in 4Q22 for RAPIDe-1, a global Phase 2 study of PHVS416 for the acute treatment of HAE attacks ongoing outside the U.S. ? Executing from a strong financial |
|
| September 12, 2022 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management?s Discussion and Analysis of Financial Condition and Results of Operations This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| September 12, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of prin |
|
| September 12, 2022 |
Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements As of and for the three and six months ended June 30, 2022 Table of Contents Contents Unaudited condensed consolidated statements of profit or loss and other comprehensive income or loss 3 Unaudited condensed consolidated statements of financial position 4 Unaudited condensed consolidated statements of change |
|
| August 22, 2022 |
Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S. Exhibit 99.1 Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S. Zug, Switzerland, August 22, 2022 ? Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that the U.S. Food and Drug Administration (FDA) verbally informed Pharvaris that, based on |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive offic |
|
| July 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive office) |
|
| July 13, 2022 |
Exhibit 99.1 Pioneering science for patient choice July 2022 ? 2022 ? 2022 Disclaimer This Presentation may contain certain ?forward?looking statements? within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do not relate to matters of historical fact should be considered forward-looking statements incl |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive offic |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive office) |
|
| June 14, 2022 |
Pharvaris Announces Annual Meeting of Shareholders Exhibit 99.1 Pharvaris Announces Annual Meeting of Shareholders Zug, Switzerland, June 14, 2022 ? Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced the annual general meeting of shareholders will take place on Wednesday, June |
|
| June 14, 2022 |
6-K 1 phvs-6k20220614.htm 6-K- AGM UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Add |
|
| June 14, 2022 |
Exhibit 99.3 VOTING PROXY THE UNDERSIGNED Name: Address: acting on behalf of (only to be completed if relevant) Name: Address: (the "Principal"). DECLARES AS FOLLOWS 1. The Principal hereby registers for the annual general meeting of shareholders of Pharvaris N.V. (the "Company") to be held on June 29, 2022 at 4:00 p.m. CEST at J.H. Oortweg 21, 2333 CH Leiden, the Netherlands (the "AGM") and, for |
|
| June 14, 2022 |
Exhibit 99.2 CONVENING NOTICE This is the convening notice for the annual general meeting of shareholders of Pharvaris N.V. (the "Company") to be held on June 29, 2022 at 4:00 p.m. CEST at J.H. Oortweg 21, 2333 CH Leiden, the Netherlands (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch statutory board report for the fiscal year ended December 31, 2021 (discussio |
|
| May 11, 2022 |
6-K 1 phvs-6k20220511.htm 6-K - PRESS RELEASE CLO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) J.H. Oortweg 21 2333 CH Leiden The Ne |
|
| May 11, 2022 |
Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights Exhibit 99.1 Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights ? Target enrollment achieved in RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks; top-line data anticipated in 4Q22 ? Enrollment underway in HAE CHAPTER-1, proof-of-concept Phase 2 prophylactic study using PHVS416 for the prevention of HAE attacks; top-line data anticip |
|
| May 11, 2022 |
Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer Exhibit 99.1 Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer ? Pharvaris? executive team further strengthened by Ms. Schmidt?s deep international experience and biopharmaceutical industry tenure ZUG, Switzerland, May 11, 2022 ? Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its |
|
| May 11, 2022 |
Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements At March 31, 2022 Contents Unaudited condensed consolidated statements of profit or loss and other comprehensive income 3 Unaudited condensed consolidated statements of financial position 4 Unaudited condensed consolidated statements of changes in equity 5 Unaudited condensed consolidated statements of cash f |
|
| May 11, 2022 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| May 11, 2022 |
6-K 1 phvs-6k20220511.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address o |
|
| March 29, 2022 |
Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Berndt Modig, certify that: 1. I have reviewed this annual report on Form 20-F of Pharvaris N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a m |
|
| March 29, 2022 |
EXHIBIT 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Pharvaris N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anna Nijdam, Head of Finance and Principal Accounting Officer |
|
| March 29, 2022 |
Exhibit 99.1 Pharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights ? Phase 1 pharmacokinetics study demonstrates PHVS719 well tolerated with extended-release profile supporting once-daily dosing ? Orphan Drug Designation for PHA121 granted by FDA ? RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks ongoing; top-line data a |
|
| March 29, 2022 |
Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002. EXHIBIT 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Anna Nijdam, certify that: 1. I have reviewed this annual report on Form 20-F of Pharvaris N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a ma |
|
| March 29, 2022 |
EXHIBIT 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Pharvaris N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Berndt Modig, Chief Executive Officer of the Company, certify |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive office |
|
| March 29, 2022 |
Consent of PricewaterhouseCoopers Accountants N.V. Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. “333-252897”) and Form F-3 (No. “333-263198”) of Pharvaris N.V. of our report dated March 29, 2022 relating to the financial statements, which appears in this Form 20-F. /s/ R.M.N. Admiraal RA PricewaterhouseCoopers Accountants N. |
|
| March 29, 2022 |
Description of Ordinary Shares of the Registrant Exhibit 2.1 Description of Ordinary Shares of the Registrant As of the date of the Annual Report on Form 20-F of which this Exhibit 2.1 is a part, Pharvaris N.V. (the ?Company?, ?we?, ?us? or ?our?) has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended; our registered ordinary shares. We are registered with the Trade Register of the Chamber |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents ;caia UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 15, 2022 |
Up to $75,000,000 Ordinary shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263198 PROSPECTUS SUPPLEMENT (To Prospectus dated March 10, 2022) Up to $75,000,000 Ordinary shares We have entered into a sales agreement, with SVB Securities LLC, or SVB Leerink, dated March 1, 2022 (the ?Sales Agreement?), relating to the sale of our ordinary shares offered by this prospectus supplement and the accompanying |
|
| March 8, 2022 |
Pharvaris N.V. J.H. Oortweg 21 2333 CH Leiden, The Netherlands March 8, 2022 Pharvaris N.V. J.H. Oortweg 21 2333 CH Leiden, The Netherlands March 8, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Pharvaris N.V. Registration Statement on Form F-3 Filing Date March 1, 2022 File No. 333-263198 REQUEST FOR ACCELERATION OF EFFECTIVENESS Pursuant to Rule 461 under the Securities Act of 1933, as amen |
|
| March 2, 2022 |
Exhibit 4.2 Pharvaris N.V. as the Company and [ ] as Trustee Senior Indenture Dated as of [ ], [ ] TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 5 ARTICLE 2 THE SECURITIES Section 2.01. Form and Dating 5 Se |
|
| March 2, 2022 |
Form of Subordinated Indenture Exhibit 4.3 Pharvaris N.V. as the Company and [ ] as Trustee Subordinated Indenture Dated as of [ ], [ ] TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions 1 Section 1.02. Other Definitions 5 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 6 ARTICLE 2 THE SECURITIES Section 2.01. Form and Datin |
|
| March 2, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 2, 2022 |
Sales Agreement, dated as of March 1, 2022, between Pharvaris N.V. and SVB Securities LLC Exhibit 1.2 PHARVARIS N.V. Ordinary Shares (nominal value of ?0.12 per share) SALES AGREEMENT March 1, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Pharvaris N.V., a public limited liability company (naamloze vennootschap) (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Securities LLC (the ?Agent?), as follows: 1 |
|
| March 2, 2022 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form F-3 (Form Type) Pharvaris N. |
|
| February 14, 2022 |
PHVS / Pharvaris N.V. / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Pharvaris N.V. (Name of Issuer) Ordinary shares, par value ?0.12 par value per share (Title of Class of Securities) N69605108 |
|
| February 11, 2022 |
PHVS / Pharvaris N.V. / Foresite Capital Fund IV, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Pharvaris N.V. (Name of Issuer) Ordinary Shares, par value ?0.01 (Title of Class of Securities) N69605108 (CUSIP Number) December 31, 2021 (Date of Event Wh |
|
| February 3, 2022 |
Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. |
|
| February 3, 2022 |
PHVS / Pharvaris N.V. / LSP V Cooperatieve U.A. - SC 13G Passive Investment SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Pharvaris, N.V. (Name of Issuer) Ordinary Shares (Title of Class of Securities) N69605108 (CUSIP Number) De |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive offi |
|
| January 10, 2022 |
Exhibit 99.1 Pioneering science for patient choice January 2022 ? 2022 ? 2022 Disclaimer This Presentation may contain certain ?forward?looking statements? within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements other than statements of historical factors contained in this Presentation, including statements regarding our future financial c |
|
| December 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE13-A16 OR 15D-16 UNDER The SECURITIES EXCHANGE ACT OF 1934 For the Month of December, 2021 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive off |
|
| December 22, 2021 |
Pharvaris Announces Changes to its Board of Directors Exhibit 99.1 Pharvaris Announces Changes to its Board of Directors Zug, Switzerland, Dec. 22, 2021 ? Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the appointment of Anne Marie |
|
| December 7, 2021 |
6-K 1 d222757d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE13-A16 OR 15D-16 UNDER The SECURITIES EXCHANGE ACT OF 1934 For the Month of December, 2021 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address o |
|
| December 7, 2021 |
Pharvaris Announces Changes to its Board of Directors Exhibit 99.1 Pharvaris Announces Changes to its Board of Directors Zug, Switzerland, December 7, 2021 ? Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the appointment of Elisabet |
|
| November 10, 2021 |
Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights Exhibit 99.1 Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights ? RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks, proceeding; topline data reaffirmed for 2022 ? CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of HAE attacks, recruiting; topline data expected in 2022 ? PHVS719 Phase 1 pharmacokinetics study init |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive off |
|
| November 10, 2021 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management?s Discussion and Analysis of Financial Condition and Results of Operations This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| November 10, 2021 |
Three months ended September 30 Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements At September 30, 2021 Contents Unaudited condensed consolidated statements of profit or loss and other comprehensive income 3 Unaudited condensed consolidated statements of financial position 4 Unaudited condensed consolidated statements of changes in equity 5 Unaudited condensed consolidated statements of ca |
|
| July 30, 2021 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management?s Discussion and Analysis of Financial Condition and Results of Operations This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive office) |
|
| July 30, 2021 |
Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights Exhibit 99.1 Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights ? RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks expanding to US, expected to report data in 2022 ? CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of HAE attacks, and PHVS719 Phase 1 PK study expected to initiate in 2021 ? Executing from a strong |
|
| July 30, 2021 |
Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements At June 30, 2021 Contents Unaudited condensed consolidated statements of profit or loss and other comprehensive income 3 Unaudited condensed consolidated statements of financial position 4 Unaudited condensed consolidated statements of changes in equity 5 Unaudited condensed consolidated statements of cash fl |
|
| July 1, 2021 |
Exhibit 99.1 Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 Zug, Switzerland, July 1, 2021 ? Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-med |
|
| July 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive office) |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive office) |
|
| June 11, 2021 |
Exhibit 99.2 CONVENING NOTICE This is the convening notice for the annual general meeting of shareholders of Pharvaris N.V. (the "Company") to be held on June 29, 2021 at 1:00 p.m. CEST at J.H. Oortweg 21, 2333 CH Leiden, the Netherlands (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch statutory board report for the fiscal year ended December 31, 2020 (discussio |
|
| June 11, 2021 |
Pharvaris Announces Annual Meeting of Shareholders Exhibit 99.1 Pharvaris Announces Annual Meeting of Shareholders Zug, Switzerland, June 11, 2021 ? Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the annual general meeting of sha |
|
| June 11, 2021 |
Exhibit 99.3 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the "Principal"). DECLARES AS FOLLOWS 1. The Principal hereby registers for the annual general meeting of shareholders of Pharvaris N.V. (the "Company") to be held on June 29, 2021 at 1:00 p.m. CEST at J.H. Oortweg 21, 2333 CH Leiden, the Netherlands (the "AGM") and, |
|
| June 11, 2021 |
6-K 1 phvs-6k20210610.htm 6-K2020 ANNUAL ACCOUNTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) J.H. Oortweg 21 2333 CH Leiden The N |
|
| May 26, 2021 |
Exhibit 99.3 Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements At March 31, 2021 Contents Unaudited condensed consolidated statements of profit or loss and other comprehensive income 2 Unaudited condensed consolidated statements of financial position 4 Unaudited condensed consolidated statements of changes in equity 5 Unaudited condensed consolidated statements of cash f |
|
| May 26, 2021 |
Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights Exhibit 99.1 Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights ? RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks proceeding ? HAE CHAPTER-1, Phase 2 prophylactic study of PHVS416 for prevention of HAE attacks, on-track to initiate in 2021 ? Viviane Monges nominated to Board of Directors and as Chair of the Audit Committee ? Strong |
|
| May 26, 2021 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management?s Discussion and Analysis of Financial Condition and Results of Operations This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes there |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant?s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of principal executive office) |
|
| May 12, 2021 |
6-K 1 d853324d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) J.H. Oortweg 21 2333 CH Leiden The Netherlands (Address of pri |
